Where Will Beyond Meat Stock Be in 3 Years?

Beyond Meat's revenue fell from $465 million in 2021 to $276 million in 2025, while adjusted EBITDA worsened from -$113 million to -$178 million and gross margin collapsed from 25.2% to 2.8%. Analysts expect revenue to decline further to $253 million by 2028, though EBITDA may improve to -$74 million as costs are cut. The article argues the stock could still be overvalued at 3x sales and may face delisting by 2029 unless a reverse split lifts the share price above $1.

Analysis

BYND is moving from a growth-collapse story into a financing-and-liquidity story. Once a consumer brand starts trading near cash-burning distress levels, the stock stops being driven by unit economics and starts being driven by the probability of another dilutive capital raise, reverse split, or covenant pressure; that path tends to favor option sellers and short sellers on rallies rather than outright buyers. The important second-order effect is that every incremental attempt to preserve distribution via discounting weakens the category price umbrella, which can force competitors to trade margin for shelf space and ultimately slow any industry normalization.

The biggest beneficiary is not a named peer but traditional protein and private-label protein, which can absorb share without having to defend a brand-premium narrative. For PEP, the direct P&L hit is likely immaterial, but the strategic lesson is that adjacent partnerships with distressed CPG assets carry reputational and execution risk; management teams will demand tighter hurdle rates and more structured downside protection on future JV experiments. If BYND keeps shrinking, its reduced scale could also make retailer resets easier, accelerating shelf rationalization in favor of faster-turn, higher-margin items.

The key catalyst path is asymmetric: upside requires several things to go right simultaneously over 12-24 months, while downside can happen quickly on a failed capital raise, another guidance cut, or an exchange-compliance headline. A reverse split may mechanically defer delisting risk, but it often worsens liquidity and attracts a lower-quality shareholder base, which can increase volatility rather than fix fundamentals. Consensus is likely underestimating how hard it is for a company with persistent negative EBITDA and falling revenue to stabilize gross margin without either conceding more volume or raising prices into a demand-elastic customer base.

Key Decisions for Investors

• Short BYND into strength on any 20-30% rally; use a 3-6 month horizon and cover if management announces a credible financing package or if gross margin inflects for two consecutive quarters.
• Buy BYND put spreads 6-12 months out to capture dilution/delisting risk while limiting theta burn; best risk/reward if implied volatility stays elevated but not extreme.
• For a cleaner relative-value expression, long private-label / traditional protein exposure versus short BYND through a basket of consumer staples or food names with stable margins; thesis is shelf-share migration over 12-24 months.
• Do not chase PEP on this headline; the direct impact is too small, but monitor future venture/JV disclosures as a signal that large CPGs will demand stricter terms on innovation bets.
• Set a hard risk trigger to reduce shorts if BYND executes a reverse split plus an equity raise, since that can mechanically lift the stock and force a tactical squeeze even as fundamentals remain weak.